More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is to make ...
MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results